Meeting
2012 Breast Cancer Symposium
Correlation of receptor activator of nuclear factor kappa b (RANK) expression in breast cancer (BC) at the time of diagnosis with recurrence-free survival (RFS) and risk of bone-dominant metastases (BDM) in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657).
Authors
Jiali Li
University of California, San Francisco Helen Dill
Jiali Li , Christina Yau , Michael Campbell , Laura Esserman , John Park , Hope Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A
Track
Risk Assessment, Prevention, Detection, and Screening
Sub Track
Genomics
Citation
J Clin Oncol 30, 2012 (suppl 27; abstr 2)
DOI
10.1200/jco.2012.30.27_suppl.2
Abstract #
2
Poster Bd #
A4
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in prostate cancer (PC) and breast cancer (BC).
First Author: P. Hadji
Poster
2014 ASCO Annual Meeting
RANKL circulating levels in the evaluation of bone response in breast cancer (BC) patients.
First Author: Toni Ibrahim
Poster
2012 ASCO Annual Meeting
Genetic polymorphisms of the OPG gene associated with breast cancer.
First Author: Gunter Assmann
Poster
2011 ASCO Annual Meeting
Circulating levels of RANK/RANKL and OPG in patients with bone metastasis treated with zoledronic acid: A prospective study.
First Author: T. Ibrahim